beginner12 min read

What Is a PDUFA Date? Everything Biotech Investors Need to Know

If you've ever watched a biotech stock jump 40% or crash 60% overnight, there's a good chance a PDUFA date was involved. PDUFA dates are the single most predictable, highest-impact events in biotech investing — and understanding them is essential for anyone who trades pharmaceutical stocks. This guide explains what PDUFA dates are, how they work, why they move stocks so dramatically, and how experienced biotech investors use them to make money. No jargon without explanation, no assumptions about what you already know. By the end, you'll understand the FDA approval timeline better than most retail investors.

What PDUFA actually stands for (and why it exists)

PDUFA stands for the Prescription Drug User Fee Act, a law first passed in 1992 that fundamentally changed how the FDA reviews new drugs. Before PDUFA, the FDA had no deadline for reviewing drug applications. Companies would submit their data and wait — sometimes for years — with no guaranteed timeline. PDUFA solved this by requiring pharmaceutical companies to pay fees when they submit a drug application. In exchange, the FDA commits to reviewing the application within a specific timeframe. For standard new drug applications, the FDA has 10 months to complete its review. For Priority Review drugs (which address serious conditions with unmet need), the timeline is shortened to 6 months. The PDUFA date (sometimes called the 'PDUFA action date' or 'target action date') is the specific calendar date by which the FDA has committed to making a decision on a drug application. This decision is binary: approve the drug, or issue a Complete Response Letter (CRL) explaining why it wasn't approved. This binary outcome on a known date is why PDUFA dates are so important for investors. You know exactly when the decision is coming, and the outcome will be either very good or very bad for the stock.

Key takeaway

A PDUFA date is the FDA's deadline to decide on a drug approval. It's a known date with a binary outcome — approve or reject — which is why biotech stocks move so dramatically around these events.

Example

When the FDA approved Vertex's Casgevy (the first CRISPR gene editing therapy) on December 8, 2023, the PDUFA date had been publicly known for months. Investors who tracked this date were positioned before the decision.

How the PDUFA timeline works, step by step

The journey from drug submission to PDUFA date follows a predictable sequence: 1. The company submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA, along with the PDUFA user fee (currently around $4 million). 2. Within 60 days, the FDA completes a 'filing review' to determine if the application is complete enough to review. If accepted, the FDA assigns the PDUFA action date — typically 10 months from submission (or 6 months for Priority Review). 3. During the review period, FDA scientists evaluate all clinical trial data, manufacturing information, and proposed labeling. The company may receive 'information requests' asking for additional data. 4. About 3 months before the PDUFA date, the FDA may convene an Advisory Committee (AdCom) meeting where external experts vote on whether the drug should be approved. AdCom votes are non-binding but highly influential. 5. On or before the PDUFA date, the FDA takes one of three actions: (a) Full Approval, (b) Tentative Approval (for generic drugs with patent issues), or (c) Complete Response Letter (CRL) explaining deficiencies. Importantly, the FDA often acts BEFORE the PDUFA date. Approvals frequently come days or even weeks early. Complete Response Letters typically arrive on or very close to the PDUFA date. This creates an asymmetry: early action usually means good news.

Key takeaway

The FDA usually takes action before the PDUFA deadline. Early decisions are often approvals, while decisions on the actual PDUFA date or shortly after are more likely to be rejections (CRLs).

Example

Eli Lilly's Zepbound (tirzepatide for obesity) was approved on November 8, 2023 — five days before its November 13 PDUFA date. The early approval signaled strong FDA confidence and the stock jumped immediately.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

Why PDUFA dates move stocks 20-60%

The stock impact of PDUFA dates is driven by a few key factors: Binary outcome with massive commercial implications: An approval transforms a company from one that spends money on R&D to one that can generate revenue. For a small biotech with a single product, approval literally determines whether the company has a future. Information asymmetry collapses: Before the PDUFA date, the stock price reflects the market's estimate of approval probability. If the market prices in a 70% chance of approval, and the drug IS approved, the stock re-rates to reflect 100% certainty — a significant jump. If it's rejected, the stock crashes to reflect 0%. Short squeezes and momentum: PDUFA dates attract options traders and short sellers. An unexpected approval can trigger massive short covering, amplifying the move. Similarly, unexpected CRLs can create cascading sell-offs. Label details matter: Even when approval is expected, the specific approved indication, any black box warnings, and REMS (Risk Evaluation and Mitigation Strategy) requirements can significantly affect commercial potential. A 'clean label' gets a bigger stock pop than a 'restricted label.' Historical data shows that small-cap biotech stocks move an average of 30-40% on PDUFA days. Large-cap stocks with diversified portfolios move less (5-15%) because a single product matters less to their overall value.

Key takeaway

PDUFA dates cause large stock moves because they resolve uncertainty about a drug's commercial future in a single moment. The smaller the company and the more important the drug, the larger the move.

Example

When the FDA rejected MDMA-assisted therapy for PTSD in August 2024, Lykos Therapeutics (the sponsor) saw its plans for an IPO collapse entirely. A single CRL ended the company's near-term prospects.

How to find upcoming PDUFA dates

There are several reliable sources for tracking PDUFA dates: FDA's official PDUFA date list is available but can be difficult to navigate. The FDA publishes tentative PDUFA dates in its CDER calendar, but the format isn't investor-friendly. BioPharmCatalyst.com maintains the most popular free PDUFA calendar among retail investors, showing upcoming FDA decisions with company information, drug details, and indication. BPIQ.com offers a catalyst database with PDUFA dates for 600+ micro to mid-cap biotechs, filtered by phase, therapeutic area, and market cap. ClinicalInvestor.com (that's us) provides a free catalyst calendar that includes not just PDUFA dates but also Phase 3 data readouts, conference presentations, and advisory committee meetings — all with plain-English explanations of what to expect. Company press releases and SEC filings (Form 8-K) are the primary sources. When a company receives a PDUFA date, they're required to disclose it. Look for press releases with language like 'FDA accepts NDA with PDUFA action date of [date].' Pro tip: Set up Google Alerts for '[company name] PDUFA' and '[company name] FDA' for any biotech stocks you're tracking. You'll get notified as soon as dates are announced or updated.

Key takeaway

Track PDUFA dates through specialized biotech calendars like ClinicalInvestor's catalyst calendar, BioPharmCatalyst, or BPIQ. Never rely on memory — set alerts and check calendars weekly.

Example

ClinicalInvestor's April 2026 catalyst calendar shows 10 significant events including PDUFA decisions, Phase 3 readouts, and conference presentations — each with plain-English analysis of what to expect.

Common strategies for trading PDUFA dates

Experienced biotech investors use several approaches around PDUFA dates: The catalyst run-up trade: Buy 3-6 weeks before a PDUFA date when sentiment is building, sell shortly before the actual date. This captures the anticipation premium without holding through the binary event. Statistics show that stocks with upcoming PDUFA dates tend to drift upward in the weeks before the decision, especially for high-probability approvals. The hold-through approach: If you have high conviction in approval (strong Phase 3 data, positive AdCom vote, unmet medical need), you hold through the PDUFA date. This captures the full approval pop but exposes you to devastating downside on a CRL. The options straddle: Buy both call and put options before the PDUFA date, profiting from the large move regardless of direction. This strategy is expensive because options premiums are inflated before PDUFA dates (high implied volatility), but it works when the actual move exceeds what the options market predicted. The post-event fade: Wait for the PDUFA outcome, then trade the overreaction. Stocks that jump 50% on approval sometimes fade 10-20% in the following weeks as initial excitement wears off. Similarly, CRL-driven crashes sometimes partially recover as investors digest the details. The one rule every experienced biotech trader follows: never risk more than you can afford to lose on a single PDUFA date. These are binary events. Even the highest-probability approvals can fail.

Key takeaway

Most experienced traders prefer the catalyst run-up strategy — buying before and selling before the PDUFA date — because it captures upside without binary risk. Only hold through a PDUFA if you're prepared for a total loss scenario.

Example

A trader who bought Praxis Precision Medicine (PRAX) 4 weeks before its essential tremor PDUFA date would have captured the anticipation run-up. Selling the day before the PDUFA date locks in the premium without binary risk.

Key terms

PDUFA

Prescription Drug User Fee Act — the law that requires the FDA to review drug applications within a specific timeframe in exchange for user fees paid by pharmaceutical companies.

NDA

New Drug Application — the formal submission a company makes to the FDA requesting approval to market a new drug. Contains all clinical trial data, manufacturing details, and proposed labeling.

BLA

Biologics License Application — the equivalent of an NDA but for biologic drugs (antibodies, gene therapies, cell therapies). Filed with FDA's CBER division.

CRL

Complete Response Letter — the FDA's formal rejection letter explaining why a drug application was not approved and what additional data or actions are needed.

Priority Review

An expedited FDA review pathway (6 months instead of 10) for drugs that treat serious conditions with significant unmet need. Does not guarantee approval.

AdCom

Advisory Committee — a panel of external experts convened by the FDA to vote on whether a drug should be approved. Votes are non-binding but the FDA follows AdCom recommendations about 80% of the time.

REMS

Risk Evaluation and Mitigation Strategy — special safety requirements the FDA can impose as a condition of approval, such as restricted distribution, mandatory patient counseling, or physician certification.

Action Date

The specific calendar date by which the FDA has committed to completing its review of a drug application. This is the PDUFA date.

Filing Review

The FDA's initial 60-day review to determine if a drug application is complete enough to proceed to full review. Successful filing is called 'acceptance for review.'

Breakthrough Therapy Designation

An FDA program that expedites development and review for drugs that show substantial improvement over existing therapies. Companies with this designation get more FDA interaction, not faster PDUFA dates.

Next steps

Bookmark ClinicalInvestor's catalyst calendar and check it every Sunday to know what PDUFA dates are coming in the next 4-6 weeks

For any biotech stock you own, look up whether it has a PDUFA date in the next 6 months — if so, decide now whether you'll hold through or trade the run-up

Set up Google Alerts for 'PDUFA' plus the ticker symbols of biotech stocks you follow

Read the company's press release about its NDA/BLA submission to understand whether the drug has Priority Review (6 months) or Standard Review (10 months)

Check whether an Advisory Committee meeting is scheduled before the PDUFA date — AdCom votes give you a preview of the FDA's likely decision

Keep learning

How to Read Clinical Trial Results: A Beginner's Guide →Biotech Investing 101: The Complete Beginner's Guide →Understanding Phase 1, 2, and 3 Clinical Trials →Catalyst Trading Strategies for Biotech Stocks →